This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ishida, K. Articles by Osada, H. Search for Related Content PubMed PubMed Citation Articles by Ishida, K. Articles by Osada, H.

¹ Antibiotics Laboratory, RIKEN Discovery Research Institute, Saitama, Japan; ² Hanno Discovery Center, Taiho Pharmaceutical Co., Ltd., Saitama, Japan; ³ Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Miyagi, Japan; and ⁴ Graduate School of Science and Engineering, Saitama University, Saitama, Japan

Requests for reprints: Hiroyuki Osada, Antibiotics Laboratory, RIKEN Discovery Research Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan. Phone: 81-48-467-9541; Fax: 81-48-462-4669. E-mail: hisyo{at}riken.jp

Heparanase is an endo-ß-D-glucuronidase that degrades heparan sulfate glycosaminoglycans in the extracellular matrix and the basement membrane and is well known to be involved in tumor cell invasion and angiogenesis. We have focused on heparanase as a target for antitumor agents, especially antimetastatic agents. (R)-3-hexadecanoyl-5-hydroxymethyltetronic acid (RK-682) was found to display an inhibitory activity against heparanase in our screening of natural sources. Because RK-682 has been reported to show inhibitory activities against several enzymes, we have tried to develop selective heparanase inhibitors using the method of rational drug design. Based on the structure of the heparanase/RK-682 complex, we speculated that selective inhibitory activity against heparanase could be acquired by arylalkylation, namely, by benzylation of the 4-position of RK-682. Among the rationally designed 4-alkyl-RK-682 derivatives, 4-benzyl-RK-682 has been found to possess a selective inhibitory activity for heparanase (IC₅₀ for heparanase, 17 µmol/L; IC₅₀ for other enzymes, >100 µmol/L). 4-Benzyl-RK-682 also inhibited the invasion and migration of human fibrosarcoma HT1080 cells (IC₅₀ for invasion, 1.5 µmol/L; IC₅₀ for migration, 3.0 µmol/L). On the other hand, RK-682 had no inhibitory effect on the invasion and migration of HT1080 cells at doses of up to 100 µmol/L.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 12/26/03; revised 5/18/04; accepted 7/ 6/04.

This article has been cited by other articles:

				S. Simizu, T. Suzuki, M. Muroi, N. S. Lai, S. Takagi, N. Dohmae, and H. Osada Involvement of Disulfide Bond Formation in the Activation of Heparanase Cancer Res., August 15, 2007; 67(16): 7841 - 7849. [Abstract] [Full Text] [PDF]

				I. Cohen, B. Maly, I. Simon, A. Meirovitz, E. Pikarsky, E. Zcharia, T. Peretz, I. Vlodavsky, and M. Elkin Tamoxifen Induces Heparanase Expression in Estrogen Receptor Positive Breast Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4069 - 4077. [Abstract] [Full Text] [PDF]

				X. Xu, G. Rao, R. M. Quiros, A. W. Kim, H.-Q. Miao, G. J. Brunn, J. L. Platt, P. Gattuso, and R. A. Prinz In Vivo and in Vitro Degradation of Heparan Sulfate (HS) Proteoglycans by HPR1 in Pancreatic Adenocarcinomas: LOSS OF CELL SURFACE HS SUPPRESSES FIBROBLAST GROWTH FACTOR 2-MEDIATED CELL SIGNALING AND PROLIFERATION J. Biol. Chem., January 26, 2007; 282(4): 2363 - 2373. [Abstract] [Full Text] [PDF]

				S. Simizu, S. Takagi, Y. Tamura, and H. Osada RECK-Mediated Suppression of Tumor Cell Invasion Is Regulated by Glycosylation in Human Tumor Cell Lines Cancer Res., August 15, 2005; 65(16): 7455 - 7461. [Abstract] [Full Text] [PDF]